SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The $CAW cryptocurrency, also known as crow with knife, is trending as the community rallies behind its multi-chain functionality, bridging across $SOL, $BSC, $CRO, and $ETH (BASE) using Layerzero technology. Community members highlight its deflationary mechanisms and organic growth, while also mentioning potential staking opportunities. The focus remains on its unique branding and strong community engagement within the meme coin sector.

Bonk refers to a series of comic-style memes in which meme characters such as Doge and Cheems get hit on the head with bats, hammers and other heavy objects, accompanied by the “Bonk” sound effect and clipart. The original image that spawned the meme depicts a Shiba Inu, named Copper. Bonk brings this humor on-chain, transforming the classic meme into a tokenized digital movement powered by community and culture.

Copper Inu

Copper Inu ($COPPER) is trending amid community discussions about its chart patterns and potential for a breakout, particularly in relation to other tokens like $SOL and $BTC. Some users are pointing to its name as indicative of strength, while others express concerns about potential scams.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin is trending amidst mixed sentiment, with some users expressing frustration and others anticipating a potential uptrend. Community members are actively discussing trading strategies, staking, and the impact of broader market trends on CRO's performance, while also referencing the meme coin $CAW.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community rallies around this Solana-based meme coin, emphasizing its community-driven nature and long-term commitment with some holders staying strong for over a year. Conversations revolve around the playful "What's UpDog?" meme and promoting community engagement across various social media platforms to drive broader awareness.

Recall is a decentralized skill market for AI where communities fund, rank, and discover the AI solutions they need. Instead of corporations pushing one-size-fits-all AI, Recall flips the dynamic—communities signal demand, developers compete to deliver, and performance determines visibility.

Recall

RECALL CRYPTO is trending due to its recent ICO, with community members actively discussing its potential and current price action. High volume and new highs are fueling interest, though some caution against potential risks associated with new cryptocurrencies. The community is also comparing RECALL to other cryptocurrencies and exploring its potential within the broader crypto market.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd.

SUGP is gaining traction as traders discuss its low float and potential for a short squeeze, with comparisons being drawn to other Hong Kong-based stocks that have recently experienced significant gains. Community members are highlighting the company's regained NASDAQ compliance and a substantial contract exceeding its market capitalization as potential catalysts. The high cost to borrow is also fueling speculation about a potential squeeze.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses potential staking opportunities and meme coin integrations within its ecosystem. Conversations highlight Solana's strong setup and positive trend, with some anticipating a potential move towards new highs. Community members are also closely watching various meme coins built on Solana, such as $CAW and $UPDOG.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is buzzing as traders discuss its AI strategy and potential for long-term gains, with community members pointing to open-source AI initiatives and data center investments as key catalysts. Some traders are eyeing upcoming earnings, anticipating a significant move, while others debate short-term bearish signals versus the stock's overall bullish outlook. The stock's valuation relative to its peers and potential impact from broader market factors, including geopolitical events and interest rate decisions, are also being closely monitored.

Dominion Energy, Inc. engages in the production and distribution of energy. It operates through following business segments: Dominion Energy Virginia, Dominion Energy South Carolina, Contracted Energy, and Corporate and Other. The Corporate and Other segment focuses on corporate, service company, non-controlling interest in Dominion privatization, and non-regulated retail energy marketing operations. The company was founded by William W. Berry in 1983 and is headquartered in Richmond, VA.

Dominion Energy Inc

Dominion Energy is trending as investors weigh the impact of rising electricity demand from AI and data centers, alongside discussions about the company's dividend and strategic direction. The community is actively debating Dominion's potential within the evolving energy landscape, particularly in light of both bullish Elliott Wave analyses projecting significant upside and concerns around debt and renewable energy investments. Several analysts have adjusted their ratings and price targets, contributing to the ongoing conversation around the utility stock.

Kinder Morgan, Inc. engages in providing pipeline transportation of natural gas services. It operates through the following business segments: Natural Gas Pipelines, Products Pipelines, Terminals, and CO2. The Natural Gas Pipelines segment operates major interstate and intrastate natural gas pipelines and storage systems. The Products Pipelines segment is involved in the operation of refined petroleum products, crude oil, and condensate pipelines. The Terminals segment includes the operation of liquids and bulk terminal facilities that store and handle various commodities. The CO2 segment produces, transports, and markets to oil fields that use CO2 as a flooding medium to increase recovery and production of crude oil from mature oil fields. The company was founded by Richard D. Kinder and William V. Morgan in February 1997 and is headquartered in Houston, TX.

Kinder Morgan Inc - Ordinary Shares - Class P

Kinder Morgan is trending as investors anticipate upcoming earnings, focusing on whether the company can surpass expectations amid strong natural gas demand. The community is weighing potential volatility around the earnings release and discussing the company's growth prospects, dividend yield, and strategic positioning within the energy sector. Bullish sentiment is seen with many call option alerts and some analysts raising price targets.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Evoke Pharma's stock soared 168% on Wednesday after the company announced it had received a new U.S. patent that could extend the market life of Gimoti, its nasal spray treatment for gastroparesis.The patent, once issued, would provide Evoke with added protection through December 2036, covering the use of the drug in patients with moderate to severe symptoms of the condition.&nbsp;Gastroparesis impairs the stomach’s ability to empty, often rendering oral medications less effective.&nbsp;Evoke plans to list the new patent in the FDA’s Orange Book, which would extend exclusivity for Gimoti beyond its current timeline.The news comes alongside improving financials. In the first quarter of 2025, Evoke generated approximately $3.1 million in product sales, nearly doubling its revenue from the same period a year earlier.&nbsp;The company reported a net loss of $1.3 million, which&nbsp;translates to a loss of $0.51 per share, representing an improvement from the $1.6 million loss, or $2.09 loss per share, in the same quarter last year.Spending also ticked up, driven mainly by higher fees and profit-sharing with Eversana, its commercial partner.&nbsp;Operating expenses totaled $4.4 million, up from $3.2 million a year earlier.As of March 31, Evoke had $12.6 million in cash.&nbsp;Based on its current plans, it expects to carry operations into the second quarter of 2026.&nbsp;The company is also sticking to its 2025 sales goal of $16 million, which would be a 60% increase from last year if current trends continue.On Stocktwits, retail sentiment for Evoke was ‘extremely bullish’ amid ‘extremely high’ message volume.One user mentioned buying 100 lots of Evoke’s stock and said they were waiting for a potential move to cover.&nbsp;<stembedurl>https://stocktwits.com/mikefromclt/message/620413256</stembedurl>Another user expressed a bullish outlook as well, saying they were fully loaded on the stock and planned to hold their position into the next session.<stembedurl>https://stocktwits.com/stocksweets/message/620411085</stembedurl><a href="https://stocktwits.com/symbol/EVOK">Evoke’s stock</a> has risen 56.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Evoke Pharma (EVOK) received a new U.S. patent that could extend the market life of Gimoti/ Photo credit: Getty Images

Evoke Pharma Stock Skyrockets On Patent For Nasal Spray That Eases Stomach Delays; Retail Bulls Pile In

The newly allowed patent covers the use of Gimoti in patients with moderate to severe gastroparesis and is expected to extend market exclusivity through 2036. 

Equity

Evoke shares drop 15% as loss widens despite revenue growth

Evoke expects earnings to exceed market expectations, shares jump

Monte Rosa Therapeutics Inc. (<a class="mention" data-mention="$GLUE" data-symbol-id="GLUE" href="https://stocktwits.com/symbol/GLUE" target="_blank">$GLUE</a>)<figure class="image"><a href="https://stocktwits.com/symbol/GLUE"><img style="aspect-ratio:1284/287;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_132438_e581646ba1.png" alt="Screenshot 2024-10-28 132438.png" width="1284" height="287"></a><figcaption>Monte Rosa Therapeutic's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Shares of Monte Rosa Therapeutics surged over 130% on Monday, reaching a two-year high of $12.15 after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/glue-stock-enthralls-retail-with-novartis-licensing-deal/cJ2rnM9RJW">announcing an exclusive global licensing agreement with Novartis AG ($NVS).</a>&nbsp;The collaboration focuses on developing innovative treatments for immune-related conditions, particularly MRT-6160, an oral drug designed to inhibit the degradation of VAV1, a key signaling protein for T and B cell receptors.&nbsp;As part of the agreement, Novartis will pay $150 million upfront for exclusive worldwide rights to MRT-6160 and other VAV1-targeting molecular glues, with Monte Rosa eligible for up to $2.1 billion in milestones and tiered royalties on international sales.Retail sentiment on Stocktwits surged to ‘extremely bullish’ (97/100) with ‘extremely high’ (97/100) message volume.Evoke Pharma Inc. (<a class="mention" data-mention="$EVOK" data-symbol-id="EVOK" href="https://stocktwits.com/symbol/EVOK" target="_blank">$EVOK</a>)<figure class="image"><a href="https://stocktwits.com/symbol/EVOK"><img style="aspect-ratio:1282/282;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_132459_473ee74b09.png" alt="Screenshot 2024-10-28 132459.png" width="1282" height="282"></a><figcaption>Evoke Pharma's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Evoke Pharma’s shares were up over 30% on Monday following its presentation of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/evoke-pharma-stock-spikes-higher-on-study-data/cJ2rllaRJO">positive data for its lead drug</a>, Gimoti, as a treatment option for diabetes gastroparesis.The company ranked among the top 10 trending stocks on Stocktwits, secured the second spot for most watched, and was listed in the top 20 most active stocks&nbsp;on Monday afternoon.Evoke Pharma and its partner, Eversana, found that patients using Gimoti, a nasal version of metoclopramide, experienced significant improvements compared to those using the oral formulation. Patients who received the nasal treatment had reduced healthcare resource use and fewer healthcare visits.Retail sentiment on Stocktwits surged into ‘extremely bullish’ territory (97/100) with ‘extremely high’ (97/100) message volume.Autonomix Medical Inc. (<a class="mention" data-mention="$AMIX" data-symbol-id="AMIX" href="https://stocktwits.com/symbol/AMIX" target="_blank">$AMIX</a>)<figure class="image"><a href="https://stocktwits.com/symbol/AMIX"><img style="aspect-ratio:1271/277;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_132518_8d6392edf1.png" alt="Screenshot 2024-10-28 132518.png" width="1271" height="277"></a><figcaption>Autonomix Medical's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Shares of Autonomix skyrocketed by more than 90% on Monday morning following the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/autonomix-stock-rallies-on-strong-trial-results/cJ2rlAHRJf">announcement of positive results from its clinical trial</a> aimed at alleviating pain in pancreatic cancer patients.&nbsp;The stock became the second-highest trending on Stocktwits, just behind Trump Media &amp; Technology Group Corp. ($DJT), and was listed among the top 10 most watched stocks of the day.Retail sentiment on Stocktwits surged to ‘extremely bullish’ (97/100) with chatter escalating into ‘extremely high’ (97/100) territory.For updates and corrections email newsroom@stocktwits.com.Read more: <a href="https://stocktwits.com/news-articles/markets/equity/mstr-stock-hits-all-time-high-as-btc-crosses-68000/cJ2rj2hRJ9">MicroStrategy’s Bitcoin Holdings Drive Historic High: Retail Unfazed</a>

Retail is most bullish on these stocks today | Source: Pexels

Monte Rosa Therapeutics, Evoke Pharma, and Autonomix Medical: The Top 3 Stocks Capturing Retail Attention

Retail sentiment was particularly strong for healthcare stocks today, as Monte Rosa, Autonomix, and Evoke Pharma each announced positive developments regarding their respective innovations.

Shares of nano-cap specialty biopharma Evoke Pharma, Inc. ($EVOK) skyrocketed on Monday following its presentation of positive data for its lead drug Gimoti as a treatment option for diabetes gastroparesis.Solana Beach, California-based Evoke said on Monday that it along with its Eversana, a provider of global commercial services to the life sciences industry, presented data for GLP-1 users with diabetic gastroparesis using Gimoti at the 2024 American College of Gastroenterology annual meeting.The real-world retrospective study that evaluated the impact of Gimoti showed significant reductions across a collection of outcomes observed in patients treated with Gimoti, a nasal formulation of metoclopramide, versus oral formulation of the same, Evoke Pharma said.Patients taking nasal formulation had reduced healthcare resource utilization, and fewer healthcare visits."Our goal is to provide data regarding Gimoti as supportive care for diabetic gastroparesis for those also on GLP-1 agonists. This study, combined with the earlier real-world data presented at key conferences, reinforces GIMOTI's potential to improve outcomes for patients and reduce the overall financial burden on the healthcare system,” said Matt D’Onofrio, CEO of Evoke Pharma.<figure class="image"><a href="https://stocktwits.com/symbol/EVOK"><img style="aspect-ratio:632/132;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/evok_sentiment_973d4ea465.png" alt="evok-sentiment.png" width="632" height="132"></a><figcaption>EVOK sentiment and message volume October 28, 2024, as of 11:05 am ET | Source:&nbsp;Stocktwits</figcaption></figure>Amid the stock rally, retail sentiment toward the stock improved from ‘neutral’ a day ago to ‘extremely bullish’ (97/100) on Monday morning, with message volume spiking to ‘extremely high.’Some among the retail crowd cautioned against selling the stock and said it is worth much more than the level at which it currently traded.<stembedurl>https://stocktwits.com/Shieldsstocks/message/590294090</stembedurl>Gimoti received FDA approval as an option of alleviating symptoms in adults with acute and recurrent diabetic gastroparesis in June 2020.In the second-quarter ended June 30, 2024, Gimoti sales climbed 126% year-over-year and 47% sequentially to $2.55 million. At that time, the company revised up its 2024 net sales guidance from $11 million-$12 million to $14 million, citing the trend seen in the first half of the year.As of 11:05 a.m. ET, Evoke Pharms shares climbed 67.55% to $3.58.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/five-magnificent-seven-companies-are-due-to-release-their-quarterly-score-cards-this-week/cJ2riJORJJ">Apple, Microsoft, Google, Meta, Amazon: How’s Retail Feeling About These Big Tech Stocks Ahead Of Earnings This Week?</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

Evoke pharma presentation of real-world data for Gimoti at a conference sent its shares soaring.

Evoke Pharma's Retail Sentiment Soars As Stock Rockets On Promising Real-World Data For Gastric Disorder Drug

The real-world retrospective study that evaluated the impact of Gimoti showed significant reductions across a collection of outcomes observed in patients treated with Gimoti.

Evoke Pharma Stock Is Soaring Monday: What's Going On?

Evoke Pharma Inc (NASDAQ:EVOK) shares are trading higher Monday after the company presented GLP-1 data for users with diabetic gastoparesis using GIMOTI showing statistically significant...

Why Evoke Pharma (EVOK) Stock Is Volatile

Evoke Pharma shares were trading lower by 21.4% during Tuesday's session. The company announced a 1-for-12 reverse stock split of its common stock.
read more...

12 titoli sanitari in movimento, pre-market del 10/04/2024

Titoli in rialzo
Il titolo Evoke Pharma (NASDAQ:EVOK) ha osservato un incremento del 41,47% a 0,75 dollari durante la sessione pre-market di mercoled .
Le azioni di Jaguar Health (NASDAQ:JAGX) sono...

StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK)

StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK - Free Report) in a report issued on Tuesday. The firm issued a sell rating on the specialty pharmaceutical company's stock...

Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK - Free Report) in a research report sent to investors on Tuesday morning. The firm issued a sell rating on the specialty...

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It also develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Evoke Pharma Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

EVOK
Evoke Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest EVOK News

EVOKEvoke Pharma Inc